Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cipla
Argus Health
UBS
Cantor Fitzgerald
Julphar

Generated: July 20, 2019

DrugPatentWatch Database Preview

ARYMO ER Drug Profile

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which patents cover Arymo Er, and what generic alternatives are available?

Arymo Er is a drug marketed by Egalet and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twelve patent family members in twelve countries.

The generic ingredient in ARYMO ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

Drug patent expirations by year for ARYMO ER
Pharmacology for ARYMO ER
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for ARYMO ER
Synonyms for ARYMO ER
(5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, hydrogen sulfate (2:1)
1095-53-0
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1)
178935-96-1
57-27-2 (Parent)
64-31-3
Astramorph
Astramorph PF
Avinza
CHEBI:7003
CHEMBL2096625
DTXSID4023830
Duramorph
Duramorph PF
DY70C97N30
EINECS 200-582-8
Kapanol
l-Morphine sulfate
Morphabond
MorphaBond ER
Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt)
Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt)
MORPHINE SULFATE
Morphine Sulfate (anhydrous)
Morphine sulfate hydrate
Morphine sulfate salt solution
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
Morphine sulphate
Morphine sulphate (2:1)
Morphine, hemisulfate
MST-1 Continus
NIH 0001
NIH 10753
NSC 11441
Oramorph SR
SCHEMBL29316
Skenan
UNII-DY70C97N30

US Patents and Regulatory Information for ARYMO ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-001 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-002 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-001 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-002 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-003 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Egalet ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603-003 Jan 9, 2017 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ARYMO ER
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 15 mg, 30 mg and 60 mg ➤ Subscribe ➤ Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
Medtronic
UBS
Deloitte
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.